Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma

Accumulating evidence demonstrates that dysregulated microRNAs (miRNAs) play a critical role in tumorigenesis and progression of various cancers. miR-320b, a member of miR-320 family, was revealed downregulated in numerous human cancers, including nasopharyngeal carcinoma and colorectal cancer. Howe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology reports 2017-08, Vol.38 (2), p.959-966
Hauptverfasser: Lv, Qiao-Li, Du, Hong, Liu, Yan-Ling, Huang, Yuang-Tao, Wang, Gui-Hua, Zhang, Xue, Chen, Shu-Hui, Zhou, Hong-Hao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Accumulating evidence demonstrates that dysregulated microRNAs (miRNAs) play a critical role in tumorigenesis and progression of various cancers. miR-320b, a member of miR-320 family, was revealed downregulated in numerous human cancers, including nasopharyngeal carcinoma and colorectal cancer. However, the function of miR-320b in human glioma remained poorly defined. In this study, we report that miR-320b was lowly expressed in glioma tissues and cell lines in contrast with controls, being closely correlated with histological malignancy of glioma. Furthermore, patients with low expression of miR-320b were associated with poor prognostic outcomes. In vitro functional assays indicated that overexpression of miR-320b could markedly enhance cell apoptosis rate and suppress cell proliferation, migration and invasion. miR-320b mimic impaired cell cycle and metastasis through inhibiting the expression of G1/S transition key regulator Cyclin D1 as well as decreasing the expression level of MMP2 and MMP9. Additionally, upregulation of miR-320b could markedly promote apoptosis by increasing the level of Bax and reducing Bcl-2 expression in glioma. Taken together, our data suggested that miR-320b might serve as a novel prognostic marker and potential therapeutic target for glioma.
ISSN:1021-335X
1791-2431
DOI:10.3892/or.2017.5762